Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
The latest dividend from JNJ was $1.34 per share (ex-dividend 8/25/2026). The dividend yield over the last 12 months is 2%. Over the last 12 months there were 4 distributions, totalling $5.28 per share.